These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33068248)

  • 1. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
    Nakatani K; Matsuo H; Harata Y; Higashitani M; Koyama A; Noura M; Nishinaka-Arai Y; Kamikubo Y; Adachi S
    Int J Hematol; 2021 Feb; 113(2):243-253. PubMed ID: 33068248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
    Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
    Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a combination therapy targeting CDK4/6 and autophagy in a mouse xenograft model of t(8;21) acute myeloid leukemia.
    Matsuo H; Nakatani K; Harata Y; Higashitani M; Ito Y; Inagami A; Noura M; Nakahata T; Adachi S
    Biochem Biophys Rep; 2021 Sep; 27():101099. PubMed ID: 34430715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
    Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
    Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
    Zeng Z; Ly C; Daver N; Cortes J; Kantarjian HM; Andreeff M; Konopleva M
    Ann Hematol; 2021 Jun; 100(6):1485-1496. PubMed ID: 33787984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML.
    Hu L; Li Q; Wang J; Wang H; Ren X; Huang K; Wang Y; Liang X; Pu L; Xiong S; Zhai Z
    Mol Cancer Ther; 2024 Jul; 23(7):961-972. PubMed ID: 38507743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
    Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
    Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
    [No Abstract]   [Full Text] [Related]  

  • 10. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
    Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
    Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
    Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells.
    Yang J; Lan J; Du H; Zhang X; Li A; Zhang X; Liu Y; Zhang J; Zhang C; Ding Y; Zhang T
    Eur J Pharmacol; 2019 Mar; 846():12-22. PubMed ID: 30579933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
    Zhang Y; Hsu CP; Lu JF; Kuchimanchi M; Sun YN; Ma J; Xu G; Zhang Y; Xu Y; Weidner M; Huard J; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):675-91. PubMed ID: 25326874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
    Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
    Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
    Iriyama N; Hino H; Moriya S; Hiramoto M; Hatta Y; Takei M; Miyazawa K
    Leuk Lymphoma; 2018 Jun; 59(6):1439-1450. PubMed ID: 28918692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.